갑상선암 치료제 시장 보고서(2026년)

Thyroid cancer drugs are medications used to treat thyroid cancer by inhibiting various kinase proteins. These drugs work mainly in two ways. First, they help stop tumors from forming new blood vessels, which the tumors need for growth. They target specific proteins that cancer cells frequently produce to promote their own proliferation. Thyroid tissue consists of follicular cells and parafollicular cells, where the cancer originates.

The primary categories of thyroid cancer medications encompass radioiodine ablation, thyroid-stimulating hormone (TSH) suppression, chemotherapy, targeted multikinase therapy, and additional options. Radioiodine ablation represents a form of radiation therapy that employs radioactive iodine to eliminate or ablate any remaining healthy thyroid tissue after a thyroidectomy. Various drugs in this space include ipilimumab, cabozantinib-s-malate, Caprelsa (vandetanib), doxorubicin hydrochloride, lenvatinib mesylate, nivolumab, vandetanib, and others, which find application across settings like hospitals, oncology clinics, research organizations, and more.

Tariffs have increased the cost of imported oncology APIs and biologics used in targeted thyroid cancer therapies, including multikinase inhibitors and advanced biologic treatments. The impact is most evident in specialized therapy segments and hospital procurement channels, where pricing and supply continuity are critical. Regions such as North America and Europe have experienced higher input costs due to dependence on cross border oncology supply chains. Rising tariff related expenses have influenced procurement planning, reimbursement considerations, and treatment pricing. However, tariffs have supported domestic manufacturing, expanded local production capacity, and strengthened regional oncology drug supply chains over the long term.

The thyroid cancer drugs market research report is one of a series of new reports from The Business Research Company that provides thyroid cancer drugs market statistics, including thyroid cancer drugs industry global market size, regional shares, competitors with a thyroid cancer drugs market share, detailed thyroid cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the thyroid cancer drugs industry. This thyroid cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The thyroid cancer drugs market size has grown rapidly in recent years. It will grow from $1.32 billion in 2025 to $1.47 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to rising thyroid cancer incidence, adoption of kinase inhibitors, improved cancer diagnostics, expansion of oncology hospitals, increasing access to targeted therapies.

The thyroid cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to growth in personalized oncology drugs, rising incidence of advanced thyroid cancer, increasing clinical trial activity, expansion of immunotherapy combinations, higher oncology healthcare spending. Major trends in the forecast period include rising adoption of targeted multikinase therapies, increasing use of combination drug regimens, growing focus on advanced and refractory thyroid cancer, expansion of precision oncology treatment approaches, increased hospital-based thyroid cancer management.

Rising cases of thyroid cancer are anticipated to fuel the expansion of the thyroid cancer drugs market in the future. Thyroid cancer involves cancerous growths in the thyroid gland, necessitating prompt diagnosis and potent treatments to halt progression and spread. This uptick stems from both enhanced detection via advanced imaging and diagnostics, as well as greater exposure to environmental risks. The growing prevalence of thyroid cancer bolsters the drugs market by heightening demand for precision therapies, immunotherapies, radiopharmaceuticals, and hormone-inhibiting drugs that improve results and survival rates. For instance, in September 2025, Cancer Research United Kingdom-a UK nonprofit dedicated to cancer research and support-forecasted about 6,600 annual thyroid cancer cases by 2038-2040, with rates climbing 27% from roughly 7.3 per 100,000 people yearly in 2024-2026 to around 9.2 per 100,000. Thus, the surge in thyroid cancer incidences is propelling the thyroid cancer drugs market forward.

Leading companies in the thyroid cancer market are developing innovative therapies like selpercatinib to enhance patient treatment options and results. Selpercatinib, sold under the brand Retevmo, is a drug designed to treat cancers linked to Rearranged During Transfection (RET) mutations, such as advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For example, in September 2024, Eli Lilly and Company, a pharmaceutical firm based in the US, gained approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), the US federal agency responsible for public health protection, to treat advanced or metastatic MTC with a RET mutation. This approval covers both adult and pediatric patients aged 2 years and older who need systemic treatment. The recent traditional approval represents a major step forward in therapies for this particular thyroid cancer type.

In October 2024, Sanofi, a France-based pharmaceutical company, teamed up with Orano Med to push forward next-generation radioligand therapies for rare cancers, such as thyroid cancer. The partnership merges Sanofi's strengths in drug development with Orano Med's know-how in lead-212 (212Pb) alpha-emitting isotope-based radioligand therapies, targeting the discovery, design, and clinical advancement of innovative treatments. Orano Med, a France-based biotech firm focused on oncology, leads in targeted alpha therapies and specializes in radioligand treatments for rare cancers.

Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH

North America was the largest region in the thyroid cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the thyroid cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thyroid cancer drugs market consists of sales cabozantinib-s-malate, caprelsa, and cometriq. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thyroid Cancer Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses thyroid cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thyroid cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The thyroid cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Ipilimumab; Cabozantinib-S-Malate; Caprelsa (Vandetanib); Doxorubicin Hydrochloride; Lenvatinib Mesylate; Nivolumab; Vandetanib; Other Drug Types
• 2) By Type: Radioiodine Ablation; Thyroid Stimulating Hormone (THS) Suppression; Chemotherapy; Targeted Multikinase Therapy; Other Types
• 3) By End Users: Hospitals; Oncology Clinics; Research Organizations; Other End-Users
• Subsegments:
• 1) By Ipilimumab: Monotherapy Ipilimumab; Combination Therapy With Ipilimumab
• 2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib; Combination Therapy With Cabozantinib
• 3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC); Combination Therapy With Vandetanib
• 4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy; Liposomal Doxorubicin
• 5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC); Combination Therapy With Lenvatinib
• 6) By Nivolumab: Monotherapy Nivolumab; Combination Therapy With Nivolumab
• 7) By Vandetanib: Single-Agent Vandetanib; Combination Therapy With Vandetanib
• 8) By Other Drug Types: Sorafenib; Everolimus; Pembrolizumab
• Companies Mentioned: AbbVie Inc.; AstraZeneca PLC; Bayer AG; Bristol Myers Squibb Company; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Eli Lilly and Company; Exelixis Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals Inc.; Johnson & Johnson; Kyowa Kirin Co. Ltd.; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Amgen Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Thyroid Cancer Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Thyroid Cancer Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Thyroid Cancer Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Thyroid Cancer Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Multikinase Therapies
  • 4.2.2 Increasing Use Of Combination Drug Regimens
  • 4.2.3 Growing Focus On Advanced And Refractory Thyroid Cancer
  • 4.2.4 Expansion Of Precision Oncology Treatment Approaches
  • 4.2.5 Increased Hospital-Based Thyroid Cancer Management

5. Thyroid Cancer Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Specialty Centers
• 5.4 Research Organizations
• 5.5 Academic Medical Centers

6. Thyroid Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Thyroid Cancer Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Thyroid Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Thyroid Cancer Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Thyroid Cancer Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Thyroid Cancer Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Thyroid Cancer Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Thyroid Cancer Drugs Market Segmentation

• 9.1. Global Thyroid Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
• 9.2. Global Thyroid Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
• 9.3. Global Thyroid Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Oncology Clinics, Research Organizations, Other End-Users
• 9.4. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Ipilimumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
• 9.5. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Cabozantinib-S-Malate, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
• 9.6. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Caprelsa (Vandetanib), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
• 9.7. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Doxorubicin Hydrochloride, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Doxorubicin For Chemotherapy, Liposomal Doxorubicin
• 9.8. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Lenvatinib Mesylate, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib
• 9.9. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Nivolumab, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monotherapy Nivolumab, Combination Therapy With Nivolumab
• 9.10. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Vandetanib, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Single-Agent Vandetanib, Combination Therapy With Vandetanib
• 9.11. Global Thyroid Cancer Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sorafenib, Everolimus, Pembrolizumab

10. Thyroid Cancer Drugs Market Regional And Country Analysis

• 10.1. Global Thyroid Cancer Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Thyroid Cancer Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Thyroid Cancer Drugs Market

• 11.1. Asia-Pacific Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Thyroid Cancer Drugs Market

• 12.1. China Thyroid Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Thyroid Cancer Drugs Market

• 13.1. India Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Thyroid Cancer Drugs Market

• 14.1. Japan Thyroid Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Thyroid Cancer Drugs Market

• 15.1. Australia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Thyroid Cancer Drugs Market

• 16.1. Indonesia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Thyroid Cancer Drugs Market

• 17.1. South Korea Thyroid Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Thyroid Cancer Drugs Market

• 18.1. Taiwan Thyroid Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Thyroid Cancer Drugs Market

• 19.1. South East Asia Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Thyroid Cancer Drugs Market

• 20.1. Western Europe Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Thyroid Cancer Drugs Market

• 21.1. UK Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Thyroid Cancer Drugs Market

• 22.1. Germany Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Thyroid Cancer Drugs Market

• 23.1. France Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Thyroid Cancer Drugs Market

• 24.1. Italy Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Thyroid Cancer Drugs Market

• 25.1. Spain Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Thyroid Cancer Drugs Market

• 26.1. Eastern Europe Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Thyroid Cancer Drugs Market

• 27.1. Russia Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Thyroid Cancer Drugs Market

• 28.1. North America Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Thyroid Cancer Drugs Market

• 29.1. USA Thyroid Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Thyroid Cancer Drugs Market

• 30.1. Canada Thyroid Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Thyroid Cancer Drugs Market

• 31.1. South America Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Thyroid Cancer Drugs Market

• 32.1. Brazil Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Thyroid Cancer Drugs Market

• 33.1. Middle East Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Thyroid Cancer Drugs Market

• 34.1. Africa Thyroid Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Thyroid Cancer Drugs Market, Segmentation By Drug Type, Segmentation By Type, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Thyroid Cancer Drugs Market Regulatory and Investment Landscape

36. Thyroid Cancer Drugs Market Competitive Landscape And Company Profiles

• 36.1. Thyroid Cancer Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Thyroid Cancer Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Thyroid Cancer Drugs Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Daiichi Sankyo Company Limited Overview, Products and Services, Strategy and Financial Analysis

37. Thyroid Cancer Drugs Market Other Major And Innovative Companies

• Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH

38. Global Thyroid Cancer Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Thyroid Cancer Drugs Market

40. Thyroid Cancer Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Thyroid Cancer Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Thyroid Cancer Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Thyroid Cancer Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer